Cargando…

Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer’s disease

BACKGROUND: The relationship between biomarkers of metabolic syndrome and insulin resistance, plasma triglyceride/HDL cholesterol (TG/HDL-C) ratio, on the rate of cognitive decline in mild cognitive impairment (MCI) and dementia stages of Alzheimer’s disease (AD) is unknown. The role of peripheral a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pillai, Jagan A., Bena, James, Bekris, Lynn, Kodur, Nandan, Kasumov, Takhar, Leverenz, James B., Kashyap, Sangeeta R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018847/ https://www.ncbi.nlm.nih.gov/pubmed/36927447 http://dx.doi.org/10.1186/s13195-023-01203-y

Ejemplares similares

Key inflammatory pathway activations in the MCI stage of Alzheimer’s disease
por: Pillai, Jagan A., et al.
Publicado: (2019)

Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer’s disease
por: Pillai, Jagan A., et al.
Publicado: (2020)

Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes
por: Pillai, Jagan A., et al.
Publicado: (2021)

TNFRSF1B Gene Variants and Related Soluble TNFR2 Levels Impact Resilience in Alzheimer's Disease
por: Pillai, Jagan A., et al.
Publicado: (2021)

The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes
por: Kashyap, Sangeeta, et al.
Publicado: (2016)

Erratum to: The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes
por: Kashyap, Sangeeta, et al.
Publicado: (2016)

Association of Variation in Behavioral Symptoms With Initial Cognitive Phenotype in Adults With Dementia Confirmed by Neuropathology
por: Pillai, Jagan A., et al.
Publicado: (2022)

Impact of APOE ε4 genotype on initial cognitive symptoms differs for Alzheimer’s and Lewy body neuropathology
por: Pillai, Jagan A., et al.
Publicado: (2021)

Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage
por: Poil, Simon-Shlomo, et al.
Publicado: (2013)

The Alzheimer's Cell Atlas (TACA): A single‐cell molecular map for translational therapeutics accelerator in Alzheimer's disease
por: Zhou, Yadi, et al.
Publicado: (2022)

Outer Retinal Assessment Using Spectral-Domain Optical Coherence Tomography in Patients With Alzheimer's and Parkinson's Disease
por: Uchida, Atsuro, et al.
Publicado: (2018)

Temporal Dynamics of High-Density Lipoprotein Proteome in Diet-Controlled Subjects with Type 2 Diabetes
por: Kheniser, Karim G., et al.
Publicado: (2020)

The Media Coverage of Bruce Willis Reveals Unfamiliarity With Frontotemporal Degeneration
por: Hurley, Robert S, et al.
Publicado: (2023)

QEEG- BRAIN MAPPING - A biomarker to predict MCI/ Dementia.
por: Murugappan, SP., et al.
Publicado: (2022)

Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals
por: Chipi, Elena, et al.
Publicado: (2019)

AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery
por: Zhou, Yadi, et al.
Publicado: (2021)

Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimer’s Disease and MCI: A Review
por: Rao, Rammohan V., et al.
Publicado: (2023)

Potential Benefits of Physical Activity in MCI and Dementia
por: Nuzum, Hallie, et al.
Publicado: (2020)

In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion
por: Hessen, Erik, et al.
Publicado: (2019)

Association of Anxiety Awareness with Risk Factors of Cognitive Decline in MCI
por: Gigi, Ariela, et al.
Publicado: (2021)

Plasma Ceramides Are Elevated in Obese Subjects With Type 2 Diabetes and Correlate With the Severity of Insulin Resistance
por: Haus, Jacob M., et al.
Publicado: (2009)

Episodic Memory in Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer’s Disease Dementia (ADD): Using the “Doors and People” Tool to Differentiate between Early aMCI—Late aMCI—Mild ADD Diagnostic Groups
por: Chatzikostopoulos, Athanasios, et al.
Publicado: (2022)

MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes
por: Bettcher, Brianne M., et al.
Publicado: (2016)

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal
por: Vermunt, Lisa, et al.
Publicado: (2019)

Is the risk of Alzheimer’s disease and dementia declining?
por: Langa, Kenneth M
Publicado: (2015)

Potential role of miRNA-140 in Alzheimer’s disease
por: Akhter, Rumana, et al.
Publicado: (2019)

Survival and years of life lost in various aetiologies of dementia, mild cognitive impairment (MCI) and subjective cognitive decline (SCD) in Norway
por: Strand, Bjørn Heine, et al.
Publicado: (2018)

Social networks and their role in preventing dementia
por: Pillai, Jagan A., et al.
Publicado: (2009)

Direction of Information Flow in Alzheimer's Disease and MCI Patients
por: Vecchio, Fabrizio, et al.
Publicado: (2011)

Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease
por: Galasko, Douglas, et al.
Publicado: (2019)

Longitudinal change in regional brain volumes with exposure to repetitive head impacts
por: Bernick, Charles, et al.
Publicado: (2020)

Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and (18)F-FDG-PET imaging
por: Ottoy, Julie, et al.
Publicado: (2019)

Neuropsychological comparison of incident MCI and prevalent MCI
por: Hansen, Allison, et al.
Publicado: (2018)

Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis
por: Liss, J. L., et al.
Publicado: (2021)

FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort
por: Caminiti, Silvia Paola, et al.
Publicado: (2018)

Short IQCODE as a screening tool for MCI and dementia: Preliminary results
por: Perroco, Tíbor Rilho, et al.
Publicado: (2008)

MACE for Diagnosis of Dementia and MCI: Examining Cut-Offs and Predictive Values
por: Larner, Andrew J.
Publicado: (2019)

Biomarker testing in MCI patients—deciding who to test
por: van Maurik, Ingrid S., et al.
Publicado: (2021)

The Frontal Assessment Battery (FAB) effectively discriminates between MCI and dementia within the clinical spectrum of neurochemically confirmed Alzheimer’s disease
por: Aiello, Edoardo Nicolò, et al.
Publicado: (2022)

Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease
por: Xu, Jielin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_55klg6vdgsigo230pmvpvhvv86